Insmed, Inc. (INSM): Price and Financial Metrics


Insmed, Inc. (INSM): $23.81

-0.09 (-0.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INSM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 496

in industry

INSM POWR Grades


  • Value is the dimension where INSM ranks best; there it ranks ahead of 66.95% of US stocks.
  • The strongest trend for INSM is in Momentum, which has been heading down over the past 31 weeks.
  • INSM's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).

INSM Stock Summary

  • Of note is the ratio of INSMED Inc's sales and general administrative expense to its total operating expenses; 26.65% of US stocks have a lower such ratio.
  • INSM's price/sales ratio is 14.95; that's higher than the P/S ratio of 87.11% of US stocks.
  • INSMED Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -10.98%, greater than the shareholder yield of just 20.22% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to INSMED Inc, a group of peers worth examining would be MBII, EYPT, STIM, AVGR, and AKBA.
  • Visit INSM's SEC page to see the company's official filings. To visit the company's web site, go to www.insmed.com.

INSM Valuation Summary

  • In comparison to the median Healthcare stock, INSM's price/earnings ratio is 123.24% lower, now standing at -7.9.
  • Over the past 243 months, INSM's price/earnings ratio has gone down 5.3.
  • Over the past 243 months, INSM's price/sales ratio has gone down 2917.9.

Below are key valuation metrics over time for INSM.

Stock Date P/S P/B P/E EV/EBIT
INSM 2017-06-07 NA 7.8 -5.3 -5.0
INSM 2017-05-04 NA 9.2 -6.2 -5.9
INSM 2017-02-15 NA 4.4 -6.8 -5.7
INSM 2009-04-20 14.2 -59.0 -10.6 -11.5
INSM 2007-03-23 105.3 7.5 -1.9 -1.6
INSM 2002-06-14 270.1 1.5 -2.4 -1.1

INSM Growth Metrics

  • Its 2 year net cashflow from operations growth rate is now at -23.06%.
  • The 3 year price growth rate now stands at 157.38%.
  • Its 4 year net income to common stockholders growth rate is now at -98.28%.
INSM's revenue has moved up $167,767,000 over the prior 49 months.

The table below shows INSM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 167.767 -289.694 -319.367
2020-12-31 164.413 -219.348 -294.09
2020-09-30 168.706 -196.96 -244.865
2020-06-30 163.948 -190.66 -241.888
2020-03-31 151.425 -234.737 -246.548
2019-12-31 136.467 -250.649 -254.337

INSM Price Target

For more insight on analysts targets of INSM, see our INSM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $53.33 Average Broker Recommendation 1.39 (Strong Buy)

INSM Stock Price Chart Interactive Chart >

Price chart for INSM

INSM Price/Volume Stats

Current price $23.81 52-week high $45.44
Prev. close $23.90 52-week low $23.28
Day low $23.28 Volume 555,900
Day high $24.02 Avg. volume 1,044,229
50-day MA $27.06 Dividend yield N/A
200-day MA $34.10 Market Cap 2.46B

Insmed, Inc. (INSM) Company Bio


Insmed Incorporated is a biopharmaceutical company focused on developing targeted inhaled therapies for patients suffering from rare lung diseases. The company was founded in 1999 and is based in Bridgewater, New Jersey.


INSM Latest News Stream


Event/Time News Detail
Loading, please wait...

INSM Latest Social Stream


Loading social stream, please wait...

View Full INSM Social Stream

Latest INSM News From Around the Web

Below are the latest news stories about INSMED Inc that investors may wish to consider to help them evaluate INSM as an investment opportunity.

Non-Cystic Fibrosis Bronchiectasis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, InsMed, Zambon, Chiesi Farmaceutici and Many Others

No summary available.

AB Newswire | July 23, 2021

Inhaled Antibiotics Market 2021 In-depth Analysis by Statistics & Outlook- Lupin, Gilead Sciences, Inc, Savara Pharmaceuticals, Aradigm, Polyphor, Pharmaero, Pharmaxis Ltd, Insmed Incorporated

The Inhaled Antibiotics Market report is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection from

OpenPR | July 20, 2021

Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Analysis into Emerging Therapies and Key pharma players involved including Novartis, InsMed, Zambon, Chiesi Farmaceutici, and Many Others | DelveInsight

Non-cystic Fibrosis Bronchiectasis (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by permanent retention of mucus, dilation of bronchi, and ciliary clearance impairment. Some Clinical features include []

iCrowdNewswire | July 19, 2021

Where Do Hedge Funds Stand On Insmed Incorporated (INSM)?

No summary available.

Insider Monkey | July 19, 2021

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 12 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

Yahoo | July 8, 2021

Read More 'INSM' Stories Here

INSM Price Returns

1-mo -19.83%
3-mo -31.78%
6-mo -36.66%
1-year -8.67%
3-year -1.61%
5-year 107.95%
YTD -28.48%
2020 39.41%
2019 82.01%
2018 -57.92%
2017 135.68%
2016 -27.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8119 seconds.